Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
PYC Therapeutics Limited ( (AU:PYC) ) just unveiled an announcement.
PYC Therapeutics Limited has successfully completed the institutional component of its Entitlement Offer, raising approximately $91 million, with the total expected to reach $146 million upon the completion of the Retail Entitlement Offer. This funding will enable PYC to advance its pipeline of four first-in-class drug candidates aimed at addressing significant unmet medical needs, with human data read-outs anticipated over the next 24 months, potentially impacting its operations and market positioning significantly.
More about PYC Therapeutics Limited
PYC Therapeutics is a clinical-stage biotechnology company focused on developing RNA therapies to treat genetic diseases. Using a proprietary drug delivery platform, PYC aims to enhance the efficacy of precision medicines, particularly targeting monogenic diseases with higher success rates in clinical development.
YTD Price Performance: -2.65%
Average Trading Volume: 410,729
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$599.6M
Learn more about PYC stock on TipRanks’ Stock Analysis page.
